

APR. 14. 2005 10:04AM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 4368 P. 4

APR 14 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**JORDAN et al.**

Examiner: **Stacy Chen**

Art Unit: **1648**

Application No.: **09/989,188**

Filed: **November 21, 2001**

Title: **PROCESS FOR SCREENING  
CHEMICAL COMPOUNDS FOR  
MODULATING THE INTERACTION OF  
AN EVH1 DOMAIN**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile 703-872-9306 to the  
Commissioner for Patents, Alexandria, VA 22313, on

April 14, 2005  
Date of Transmission

[Signature]  
Signature

**AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action of December 28, 2004, the time to respond to which has been extended three months to April 28, 2005, the Applicants respond to the Restriction Requirement by provisionally electing to prosecute Group I, claims 1-20 and 47 directed to a method of identifying compounds that modulates EVH1 binding activity comprising the use of antibodies.

Should the Examiner believe that an interview would advance the prosecution of this application, the Applicants invite her to contact the undersigned at 908.231.4658.

Respectfully submitted,

Karen Krupen  
Karen I. Krupen, Reg. No. 34,647  
Attorney for Applicants

sanofi-aventis  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2000/A051 US NP